Skip to main content
Retour
Watch Compare

ABVC BIOPHARMA, INC.

Qualité des données : 100%
ABVC
Nasdaq Manufacturing Chemicals
1,38 €
▼ 0,05 € (-3,17%)
Cap. Boursière: 35,25 M
Prix
1,38 €
Cap. Boursière
35,25 M
Fourchette du Jour
1,31 € — 1,42 €
Fourchette 52 Semaines
0,81 € — 5,48 €
Volume
235 758
Ouverture 1,37 €
Moyenne 50J / 200J
1,49 €
7,44% below
Moyenne 50J / 200J
2,45 €
43,83% below

Quick Summary

Points Clés

Revenue grew 9,40% annually over 5 years — modest growth
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -2,99 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9,40%

Croissance

Revenue Growth (5Y)
9,40%
Au-dessus de la moyenne du secteur (9,35%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-82,94%
En dessous de la moyenne du secteur (-51,02%)
ROIC-43,36%
Net Margin-1551,95%
Op. Margin-1403,34%

Sécurité

Debt / Equity
0,07
En dessous de la moyenne du secteur (0,33)
Current Ratio0,63
Interest Coverage-1296,46

Valorisation

PE (TTM)
-4,46
En dessous de la moyenne du secteur (-1,98)
P/B Ratio2,92
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)
Métrique Action Médiane du Secteur
P/E -4,5 -2,0
P/B 2,9 5,1
ROE % -82,9 -51,0
Net Margin % -1552,0 -150,2
Rev Growth 5Y % 9,4 9,3
D/E 0,1 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 82,84%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 9,40% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 509 589,0 Net Income (TTM) -7,91 M
ROE -82,94% ROA -42,27%
Gross Margin 99,85% Operating Margin -1403,34%
Net Margin -1551,95% Free Cash Flow (TTM) -2,99 M
ROIC -43,36% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 0,63
Interest Coverage -1296,46 Asset Turnover 0,03
Working Capital -2,43 M Tangible Book Value 12,06 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,46 Forward P/E N/A
P/B Ratio 2,92 P/S Ratio 69,18
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -8,47%
Market Cap 35,25 M Enterprise Value 35,87 M
Per Share
EPS (Diluted TTM) -0,39 Revenue / Share 0,02
FCF / Share -0,12 OCF / Share -0,12
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 37,76%
SBC-Adj. FCF -5,74 M Growth Momentum -9,40

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 509 589,0 509 589,0 152 430,0 969 783,0 355 797,0
Net Income -7,91 M -4,90 M -10,52 M -16,42 M -12,04 M
EPS (Diluted) -0,39 -0,42 -2,43 -0,50 -0,51
Gross Profit 508 826,0 508 826,0 -149 607,0 683 368,0 350 711,0
Operating Income -7,15 M -4,71 M -8,22 M -15,11 M -11,71 M
EBITDA — — — — —
R&D Expenses 121 085,0 179 272,0 1,06 M 2,69 M 1,00 M
SG&A Expenses 2,89 M 2,26 M 5,37 M 6,07 M 5,75 M
D&A — — — 23 799,0 —
Interest Expense 5 516,0 1,31 M 2,49 M 293 968,0 227 210,0
Income Tax 24 154,0 -110 539,0 256 006,0 797 778,0 825 024,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 21,06 M 7,54 M 14,49 M 9,86 M 13,70 M
Total Liabilities 7,76 M 6,82 M 6,36 M 6,62 M 4,83 M
Shareholders' Equity 11,11 M 1,23 M 8,39 M 3,10 M 8,84 M
Total Debt 755 512,0 840 252,0 899 250,0 1,89 M 1,64 M
Cash & Equivalents 681 480,0 248 382,0 60 155,0 85 265,0 5,83 M
Current Assets 2,50 M 2,18 M 1,66 M 2,99 M 9,63 M
Current Liabilities 6,16 M 6,56 M 5,93 M 5,82 M 3,69 M